The travoprost intraocular implant demonstrated a reduction in IOP in patients with open-angle glaucoma or ocular hypertension 3 months after a single administration, according to a study published in Ophthalmology.
“The iDose is safe and effective in phakic patients with no incidence of cataract or endothelial cell loss developing during the study follow-up,” Steven R. Sarkisian Jr., MD, lead author of the study, told Healio.
In the phase 3 multicenter, randomized, double-masked, sham-controlled, noninferiority trial, participants received a fast-eluting travoprost implant (200